公开(公告)号：US20240269274A1

公开(公告)日：2024-08-15

申请号：US18406593

申请日：2024-01-08

Applicant: UCB Pharma S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  A61K33/42 ,  A61K39/00 ,  A61K45/06 ,  C07K16/18 ,  C07K16/22

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US11896667B2

公开(公告)日：2024-02-13

申请号：US17020108

申请日：2020-09-14

Applicant: UCB PHARMA, S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  C07K16/22 ,  C07K16/18 ,  A61K45/06 ,  A61K33/42 ,  A61K39/00

CPC classification number: A61K39/3955 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22 ,  A61K2039/505 ,  C07K16/18 ,  C07K2317/94

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US20210060160A1

公开(公告)日：2021-03-04

申请号：US17020108

申请日：2020-09-14

Applicant: UCB PHARMA, S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  A61K33/42 ,  A61K45/06 ,  C07K16/22

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US10799583B2

公开(公告)日：2020-10-13

申请号：US15887299

申请日：2018-02-02

Applicant: UCB PHARMA, S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  C07K16/18 ,  C07K16/22 ,  A61K45/06 ,  A61K33/42 ,  A61K39/00

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.

公开(公告)号：US20180169235A1

公开(公告)日：2018-06-21

申请号：US15887299

申请日：2018-02-02

Applicant: UCB PHARMA, S.A.

Inventor： Martyn K. Robinson

IPC: A61K39/395 ,  A61K45/06 ,  C07K16/22 ,  A61K33/42 ,  A61K39/00 ,  C07K16/18

Abstract: The invention relates to the treatment of bone disorders. In particular, the invention is directed to the use of a dosing holiday to help overcome the resistance to anti-sclerostin antibodies which develops over time when a plurality of doses of antibody are given to a subject. By giving the subject to be treated such a dosing holiday, the subject may subsequently display an increased response to a subsequent dose of the anti-sclerostin antibody. The subject may be given multiple cycles of a batch of at least two doses of anti-sclerostin antibody and a dosing holiday. In some instances, the subject may be monitored to help determine when to give the dosing holiday. Further, the subject may be given a different treatment for the bone disorder during the dosing holiday from the anti-sclerostin antibody.